Literature DB >> 24759153

Minocycline prevents osmotic demyelination associated with aquaresis.

Hiroshi Takagi1, Yoshihisa Sugimura1, Haruyuki Suzuki1, Shintaro Iwama1, Hisakazu Izumida1, Haruki Fujisawa1, Koichiro Ogawa1, Kotaro Nakashima1, Hiroshi Ochiai1, Seiji Takeuchi1, Atsushi Kiyota1, Hidetaka Suga1, Motomitsu Goto1, Ryoichi Banno1, Hiroshi Arima1, Yutaka Oiso1.   

Abstract

Overly rapid correction of chronic hyponatremia can cause osmotic demyelination syndrome (ODS). Minocycline protects ODS associated with overly rapid correction of chronic hyponatremia with hypertonic saline infusion in rats. In clinical practice, inadvertent rapid correction frequently occurs due to water diuresis, when vasopressin action suddenly ceases. In addition, vasopressin receptor antagonists have been applied to treat hyponatremia. Here the susceptibility to and pathology of ODS were evaluated using rat models developed to represent rapid correction of chronic hyponatremia in the clinical setting. The protective effect of minocycline against ODS was assessed. Chronic hyponatremia was rapidly corrected by 1 (T1) or 10 mg/kg (T10) of tolvaptan, removal of desmopressin infusion pumps (RP), or administration of hypertonic saline. The severity of neurological impairment in the T1 group was significantly milder than in other groups and brain hemorrhage was found only in the T10 and desmopressin infusion removal groups. Minocycline inhibited demyelination in the T1 group. Further, immunohistochemistry showed loss of aquaporin-4 (AQP4) in astrocytes before demyelination developed. Interestingly, serum AQP4 levels were associated with neurological impairments. Thus, minocycline can prevent ODS caused by overly rapid correction of hyponatremia due to water diuresis associated with vasopressin action suppression. Increased serum AQP4 levels may be a predictive marker for ODS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24759153     DOI: 10.1038/ki.2014.119

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

Review 1.  Neurological counterparts of hyponatremia: pathological mechanisms and clinical manifestations.

Authors:  Manuel Alfredo Podestà; Irene Faravelli; David Cucchiari; Francesco Reggiani; Silvia Oldani; Carlo Fedeli; Giorgio Graziani
Journal:  Curr Neurol Neurosci Rep       Date:  2015-04       Impact factor: 5.081

2.  Chronic Hyponatremia Causes Neurologic and Psychologic Impairments.

Authors:  Haruki Fujisawa; Yoshihisa Sugimura; Hiroshi Takagi; Hiroyuki Mizoguchi; Hideyuki Takeuchi; Hisakazu Izumida; Kohtaro Nakashima; Hiroshi Ochiai; Seiji Takeuchi; Atsushi Kiyota; Kazuya Fukumoto; Shintaro Iwama; Yoshiko Takagishi; Yoshitaka Hayashi; Hiroshi Arima; Yukio Komatsu; Yoshiharu Murata; Yutaka Oiso
Journal:  J Am Soc Nephrol       Date:  2015-09-16       Impact factor: 10.121

3.  The Spectrum of Movement Disorders in Cases with Osmotic Demyelination Syndrome.

Authors:  Dodmalur Mallikarjuna Sindhu; Vikram V Holla; Shweta Prasad; Nitish Kamble; Manjunath Netravathi; Ravi Yadav; Pramod K Pal
Journal:  Mov Disord Clin Pract       Date:  2021-06-04

4.  Osmotic Demyelination Syndrome Associated with Hypernatremia Caused by Lactulose Enema in a Patient with Chronic Alcoholism.

Authors:  Jeong Ho Lee; Chang Seong Kim; Eun Hui Bae; Soo Wan Kim; Seong Kwon Ma
Journal:  Electrolyte Blood Press       Date:  2021-06-30

5.  Central Pontine Myelinosis and Osmotic Demyelination Syndrome.

Authors:  Johann Lambeck; Maren Hieber; Andrea Dreßing; Wolf-Dirk Niesen
Journal:  Dtsch Arztebl Int       Date:  2019-09-02       Impact factor: 5.594

Review 6.  Astroglial Modulation of Hydromineral Balance and Cerebral Edema.

Authors:  Yu-Feng Wang; Vladimir Parpura
Journal:  Front Mol Neurosci       Date:  2018-06-12       Impact factor: 5.639

Review 7.  Osmotic Demyelination: From an Oligodendrocyte to an Astrocyte Perspective.

Authors:  Charles Nicaise; Catherine Marneffe; Joanna Bouchat; Jacques Gilloteaux
Journal:  Int J Mol Sci       Date:  2019-03-05       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.